白细胞介素-6抑制剂olokizumab治疗COVID-19住院患者的疗效和安全性

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI:10.32756/0869-5490-2022-2-51-56

P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev

{"title":"白细胞介素-6抑制剂olokizumab治疗COVID-19住院患者的疗效和安全性","authors":"P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev","doi":"10.32756/0869-5490-2022-2-51-56","DOIUrl":null,"url":null,"abstract":"Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19\",\"authors\":\"P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev\",\"doi\":\"10.32756/0869-5490-2022-2-51-56\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2022-2-51-56\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2022-2-51-56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Olokizumab是一种新的靶向白细胞介素6配体的人源化单克隆抗体。Olokizumab是为治疗类风湿性关节炎而开发的。在俄罗斯，它也被批准用于治疗与covid -19相关的高炎症综合征。本文介绍了两例COVID-19患者的报告，并回顾了olokizumab给药的适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19

Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical pharmacology and therapy

自引率

0.00%

发文量